Trial Profile
A Phase II Study to Evaluate the Efficacy of RAD001 in Metastatic Non-Clear Cell Renal Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jun 2012 Planned end date changed from 1 Mar 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 05 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.